Alkermes Public Limited Company Securities Litigation

If you purchased a significant amount of shares of Alkermes plc (NASDAQ: ALKS), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Alkermes plc
Date Filed:December 27th, 2018
Sector:Health Care
Industry:Major Pharmaceuticals

According to the Complaint, Alkermes is a biopharmaceutical company which researches, develops and commercializes pharmaceutical products.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the U.S. Food and Drug Administration ("FDA") had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Alkermes plc

 
First Identified Complaint

Simin Karimian, et al. v. Alkermes Public Limited Company, et al.

Date Filed:December 27th, 2018
Class Period Start:February 17th, 2017
Class Period End:November 1st, 2018
First Identified Complaint Filings
#Document TitleFiling Date